|Composition : || Each vial contains:|
.. 40mg/2ml, 100mg/5ml Water for Injection
|Indications : || It is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. |
It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
|Contraindications : || It is contraindicated in patients with a known hypersensitivity to the drug or its excipients. |
| Pharmacological action: || Irinotecan is a derivative of camptothecin. It interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. |
|Adverse Effects : ||: Abdominal discomfort, diarrhoea, Leukopenia, neutropenia, haemorrhage, body pain, insomania, dizziness, anaemia vomiting, nausea |
|Dosage : || Irinotecam should be administered as an intravenous infusion over 90 minutes for both the weekly and once-every-3-week dosage schedules. |
Weekly dose schedule: The usual starting dose is 125 mg/m2. Subsequent doses may be adjusted to as high as 150 mg/m2.
Once every three week schedule: starting dose is 350 mg.m2
| Storage: || 2-80C |
|Purity :||Not less than 99%.|